Tariff pressures shape first half results and strategy for Dr Martens
Dr Martens has reported first half revenue of £322 million ($421.7 million), broadly unchanged year on year.
Higher US import tariffs added £2.7 million ($3.53 million) in costs, with a larger impact expected across the full year, but the company says it will fully mitigate these pressures from FY27 through sourcing flexibility, cost control, and selective pricing in the US.
Gross margin improved and losses narrowed, helped by stronger full price sales and disciplined cost management. Shoe volumes rose 33 percent, and the Americas delivered the strongest growth across regions.
The company describes wholesale order books for spring and summer 2026 as healthier than last year and says it remains comfortable with full year expectations before tariffs are taken into account.
